Author details

Full Name

Claudine Isaacs

Affiliation

ORCID

Career Start Year

1983

Papers

309

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
34779303	Telephone versus in-person genetic counseling for hereditary cancer risk: Patient predictors of differential outcomes.	J Telemed Telecare	2024
34392497	Exploring Racial Differences in Treatment Decision-making in Chinese Immigrant and White American Breast Cancer Patients: the Role of Patient-Provider Communication.	Journal of Cancer Education	2023
36179271	Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study.	J Clin Oncol	2023
38095878	Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.		2023
38086377	Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.	Cell Rep Med	2023
38081141	Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in Prostate Cancer Survivors.		2023
37791898	NKG2A is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple Negative Breast Cancer.		2023
37556775	Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.	J Clin Oncol	2023
37214493	Results of a randomized controlled trial of a decision support intervention for disclosing maternal <i>BRCA</i> genetic test results to children and adolescents.	PEC Innov	2023
36585450	Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.	Nat Cancer	2023
37026029	A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor.		2023
36828705	An 8-week exercise study to improve cancer treatment related fatigue and QOL among African American breast cancer patients undergoing radiation treatment: A pilot randomized clinical trial.		2023
37146605	Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.	Cancer Cell	2023
36892847	Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.	JAMA Oncol	2023
37140922	Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer.	JAMA Netw Open	2023
36748334	Measuring high-risk parents' opinions about direct-to-consumer genetic testing for adult-onset inherited cancer syndromes in their adolescent and young adult children.	J Genet Couns	2023
36731891	BRCA1 deficiency in mature CD8<sup>+</sup> T lymphocytes impairs antitumor immunity.	J Immunother Cancer	2023
36455167	Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer.	J Clin Oncol	2023
37535880	Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer.	JCO Precis Oncol	2023
37096888	Plasma levels of interleukin-6 mediate neurocognitive performance in older breast cancer survivors: The Thinking and Living With Cancer study.	Cancer	2023
34910554	BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.	J Clin Oncol	2022
35587324	Association of markers of tumor aggressivity and cognition in women with breast cancer before adjuvant treatment: The Thinking and Living with Cancer Study.	Breast Cancer Res Treat	2022
36280642	HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.	Breast Cancer Research and Treatment	2022
35623341	Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.	Cancer Cell	2022
36125660	Molecular characterization of ESR1 variants in breast cancer.	Breast Cancer Research and Treatment	2022
35859209	Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk.	Pediatrics	2022
36456573	Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.	NPJ Breast Cancer	2022
34921700	Psychosocial impact of proactive rapid genetic counseling following breast cancer diagnosis.	Psycho-Oncology	2022
34918484	Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics.	Cancer Medicine	2022
31402434	The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families.	Journal of Cancer Education	2021
32239145	Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival.	J Natl Cancer Inst	2021
34157782	Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.	Cancer	2021
33617937	Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.	Ann Oncol	2021
34143979	Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.	Cancer Cell	2021
34251881	Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions.	Journal of Clinical Oncology	2021
34351358	Applying a Life Course Biological Age Framework to Improving the Care of Individuals With Adult Cancers: Review and Research Recommendations.	JAMA Oncol	2021
33010199	BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study.	J Genet Couns	2021
32900604	Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence score as an exemplar.	Patient Education and Counseling	2021
33400034	Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.	Breast Cancer Research and Treatment	2021
34741023	Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial.	Nat Commun	2021
34572297	Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis.	Biomedicines	2021
34732895	Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion.	Nature	2021
34565430	Improving our model of cascade testing for hereditary cancer risk by leveraging patient peer support: a concept report.	Hereditary Cancer in Clinical Practice	2021
34788629	Evaluating the impact of age on immune checkpoint therapy biomarkers.	Cell Rep	2021
34611148	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.	NPJ Breast Cancer	2021
34433020	Evaluating the impact of age on immune checkpoint therapy biomarkers.	Cell Rep	2021
34529000	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.	JAMA Oncol	2021
31526714	Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.	Clinical Breast Cancer	2020
31855498	Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221).	J Clin Oncol	2020
31894446	Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.	Breast Cancer Research and Treatment	2020